Your browser doesn't support javascript.
loading
SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
Kirsten E Lyke; Robert L Atmar; Clara P. Dominguez Islas; Christine M. Posavad; Daniel Szydlo; Rahul PaulChourdhury; Meagan E. Deming; Amanda Eaton; Lisa A. Jackson; Angela R. Branche; Hana M. El Sahly; Christina A. Rostad; Judith M Martin; Christine Johnston; Richard E. Rupp; Mark J Mulligan; Rebecca C. Brady; Robert W. Frenck; Martín Bäcker; Angelica C. Kottkamp; Tara M. Babu; Kumaravel Rajakumar; Srilatha Edupuganti; David Dobrzynski; Rhea N. Coler; Janet I. Archer; Sonja Crandon; Jillian A. Zemanek; Elizabeth R. Brown; Kathleen .M Neuzil; David S. Stephens; Diane J. Post; Seema U. Nayak; Paul C. Roberts; John Beigel; David Montefiori.
Afiliación
  • Kirsten E Lyke; University of Maryland School of Medicine, Center for Vaccine Development and Global Health
  • Robert L Atmar; Baylor College of Medicine, Departments of Medicine and Molecular Virolgy & Microbiology
  • Clara P. Dominguez Islas; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division
  • Christine M. Posavad; Fred Hutchinson Cancer Research Cneter, Department of Laboratory Medicine and Pathology, Vaccine and Infectious Diseases Division
  • Daniel Szydlo; Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP)
  • Rahul PaulChourdhury; Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP)
  • Meagan E. Deming; University of Maryland School of Medicine, Center for Vaccine Development and Global Health
  • Amanda Eaton; Duke University, Department of Surgery
  • Lisa A. Jackson; Kaiser Permanente Washington Health Research Institute
  • Angela R. Branche; University of Rochester, Department of Medicine, Division of Infectious Diseases
  • Hana M. El Sahly; Baylor College of Medicine, Departments of Molecular Virology & Microbiology and Medicine
  • Christina A. Rostad; Emory University School of Medicine, Department of Pediatrics and Center for Childhood Infections and Vaccines
  • Judith M Martin; University of Pittsburgh, Department of Pediatrics
  • Christine Johnston; Fred Hutchinson Cancer Research Center and University of Washington, Departments of Medicine and Laboratory Medicine, Vaccine and Infectious Diseases Division
  • Richard E. Rupp; University of Texas Medical Branch, Sealy Institute for Vaccine Sciences
  • Mark J Mulligan; New York University Grossman School of Medicine, NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology
  • Rebecca C. Brady; University of Cincinnati College of Medicine, Cincinnati Childrens Hospital Medical Center, Division of Infectious Diseases
  • Robert W. Frenck; University of Cincinnati College of Medicine, Cincinnati Childrens Hospital Medical Center, Division of Infectious Diseases
  • Martín Bäcker; NYU Langone Hospital, Long Island Vaccine Center Reserach Clinic and Division of Infectious Diseases, Department of Medicine
  • Angelica C. Kottkamp; NYU Grossman School of Medicine, NYU Langone Vaccine Center Bellevue Hospital Research Clinic and Division of Infectious Diseases and Immunology
  • Tara M. Babu; University of Washington, Department of Medicine, Division of Allergy and Infectious Diseases
  • Kumaravel Rajakumar; University of Pittsburgh School of Medicine, Department of Pediatrics
  • Srilatha Edupuganti; Emory University School of Medicine, Division of Infectious Diseases, Hope Clinic of Emory Vaccine Center
  • David Dobrzynski; University of Rochester, Department of Medicine, Division of Infectious Diseases
  • Rhea N. Coler; University of Washington School of Medicine, Seattle Children's Research Institute
  • Janet I. Archer; FHI360
  • Sonja Crandon; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Jillian A. Zemanek; Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP)
  • Elizabeth R. Brown; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division
  • Kathleen .M Neuzil; University of Maryland School of Medicine, Center for Vaccine Development and Global Heath
  • David S. Stephens; Emory University Department of Medicine
  • Diane J. Post; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Seema U. Nayak; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Paul C. Roberts; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • John Beigel; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • David Montefiori; Duke University, Duke Human Vaccine Institute and Department of Surgery
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22268861
ABSTRACT
As part of an ongoing study assessing homologous and heterologous booster vaccines, following primary EUA series, we assessed neutralization of D614G and Omicron variants prior to and 28 days after boost. Subset analysis was done in six combinations (N = 10/group) four homologous primary-booster combinations included mRNA-1273 two-dose priming followed by boosting with 100-g or 50-g mRNA-1273, Ad26.COV2.S single-dose priming followed by Ad26.COV2.S booster and BNT162b2 two-dose priming followed by BNT162b2 boosting; and two heterologous primary-booster combinations BNT162b2 followed by Ad26.COV2.S and Ad26.COV2.S followed by BNT162b2. Neutralizing antibody (Nab) titers to D614G on the day of boost (baseline) were detected in 85-100% of participants, with geometric mean titers (GMT) of 71-343 in participants who received an mRNA vaccine series versus GMTs of 35-41 in participants primed with Ad26.OV2.S. Baseline NAb titers to Omicron were detected in 50-90% of participants who received an mRNA vaccine series (GMT range 12.8-24.5) versus 20-25% among participants primed with Ad26.COV2.S. The booster dose increased the neutralizing GMT in most combinations to above 1000 for D614G and above 250 for Omicron by Day 29. Homologous prime-boost Ad26.COV2.S had the lowest NAb on Day 29 (D614G GMT 128 and Omicron GMT 45). Results were similar between age groups. Most homologous and heterologous boost combinations examined will increase humoral immunity to the Omicron variant.
Licencia
cc_no
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Rct Idioma: En Año: 2022 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Rct Idioma: En Año: 2022 Tipo del documento: Preprint